Alcindor T et al. Tumor volume and T2 hyperintensity changes from DeFi: A phase 3, randomized, controlled trial of nirogacestat in patients with desmoid tumors. ASCO 2023;Abstract 11514.
Chawla SP et al. Phase II randomized study of CMB305 and atezolizumab compared with atezolizumab alone in soft-tissue sarcomas expressing NY-ESO-1. J Clin Oncol 2022;40(12):1291-300. Abstract
Chen A et al. Atezolizumab and bevacizumab in patients treated with prior atezolizumab in alveolar soft tissue sarcoma (ASPS). ESMO Sarcomas and Rare Cancers Congress 2023;Abstract 49MO.
Dickson MA et al. SARC041: A phase 3 randomized double-blind study of abemaciclib versus placebo in patients with advanced dedifferentiated liposarcoma. ASCO 2023;Abstract TPS11587.
Eulo V, Van Tine BA. Immune checkpoint inhibitor resistance in soft tissue sarcoma. Cancer Drug Resist 2022;5(2):328-38. Abstract
Gounder M et al. Nirogacestat, a γ-secretase inhibitor for desmoid tumors. N Engl J Med 2023;388(10):898-912. Abstract
Gounder MM et al. RINGSIDE phase 2/3 trial of AL102 for treatment of desmoid tumors (DT): Phase 2 results. ASCO 2023;Abstract 11515.
Gounder MM et al. Initial results of phase II/III trial of AL102 for treatment of desmoid tumors (DT). ESMO 2022;Abstract 1488MO.
Grilley-Olson JE et al. A multicenter phase II study of cabozantinib + nivolumab for patients (pts) with advanced angiosarcoma (AS) previously treated with a taxane (Alliance A091902). ASCO 2023;Abstract 11503.
Haddox CL, Riedel RF. Emerging predictive biomarkers in the management of bone and soft tissue sarcomas. Exper Rev Anican Ther 2023;23(5):495-502. Abstract
Hsu JY et al. Clinical utility of CDK4/6 inhibitors in sarcoma: Successes and future challenges. JCO Precis Oncol 2022;6:e2100211. Abstract
Jones RL et al. Overall survival and long-term safety in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: Updated analyses from INTRIGUE. ASCO 2023;Abstract 11524.
Kasper B et al. DeFi: A phase III, randomized controlled trial of nirogacestat versus placebo for progressing desmoid tumors (DT). ESMO 2022;Abstract LBA2.
Kerrison WGJ et al. Current status and future directions of immunotherapies in soft tissue sarcomas. Biomedicines 2022;10(3):573. Abstract
Loong HHF et al. Updated efficacy and safety of entrectinib in patients with NTRK Fusion-positive sarcomas. Connective Tissue Oncology Society 2022;Abstract 23.
Martin Broto J et al. ImmunoSarc2: A Spanish Sarcoma Group (GEIS) phase Ib trial of doxorubicin and dacarbazine plus nivolumab in first line treatment of advanced leiomyosarcoma. ASCO 2023;Abstract 11502.
Merlini A et al. Targeting cyclin-dependent kinases in sarcoma treatment: Current perspectives and future directions. Front Oncol 2023;13:1095219. Abstract
Meyer CF. Immunotherapy for sarcoma: A work in progress. J Clin Oncol 2022;40(12):1267-70. Abstract
Naqash AR et al. Phase II study of atezolizumab in advanced alveolar soft part sarcoma (ASPS). ASCO 2021;Abstract 11519.
Reichardt P et al. Efficacy and safety of nivolumab and trabectedin in pretreated patients with advanced soft tissue sarcomas (STS): Results of a phase II trial of the German Interdisciplinary Sarcoma Group (GISG-15, NitraSarc). ASCO 2023;Abstract 11500.
Riedel RF, Agulnik M. Evolving strategies for management of desmoid tumors. Cancer 2022;128(16):3027-40. Abstract
Salkeni MA et al. A phase 2 study of an anti-PD-L1 antibody (atezolizumab) in dedifferentiated chondrosarcoma. ASCO 2023;Abstract 11533.
Van Der Graaf WTA et al. Impact of nirogacestat on pain, a key symptom in patients with desmoid tumors (DT): Results from the phase 3 DeFi study. ASCO 2023;Abstract 11564.
Van Tine BA et al. Randomized phase II trial of cabozantinib combined with PD-1 and CTLA-4 inhibition versus cabozantinib in metastatic soft tissue sarcoma. ASCO 2023;Abstract LBA11504.
Wilky BA et al. A single-arm, open-label phase 2 trial of doxorubicin plus zalifrelimab, a CTLA-4 inhibitor, with balstilimab, a PD-1 inhibitor, in patients with advanced/metastatic soft tissue sarcomas. ASCO 2023;Abstract 11501.
Wilky BA, Maleddu A. Much ado about ASPS: The rapidly changing treatment paradigms of 2022. Clin Can Res 2023;29(7):1163-6. Abstract